Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993093 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL13227574 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL2988181 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL3503119 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL3503493 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL9768573 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL3504173 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL19822058 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL668514 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA | |
| SCHEMBL28372525 | 1.00 | LMNA (0.71) | LMNAMAPTMAPK1ALDH1A1DGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106214612-A | A kind of sun-proof hand cream | 张治涛 | 2016-12-14 | — | — | CN | claimed |
| CN-106176402-A | A kind of makeup remover | 黄亚景 | 2016-12-07 | — | — | CN | claimed |
| CN-105395460-A | Efficient sun protection hand cream | QINGDAO HUAXIA HEAVY IND CO LTD | 2016-03-16 | — | — | CN | claimed |
| CN-103893093-A | Sunscreen hand cream and preparation method thereof | LI XIAOYING | 2014-07-02 | — | — | CN | claimed |
| US-20240277668-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4376835-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | TSP Therapeutics Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009261-A1 | HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS | PAZ ALBERTO (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-3528799-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | Pellficure Pharmaceuticals, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018195202-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | PELLFICURE PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| CN-105579431-B | Monoester compound and its utilization containing ether | 株式会社MORESCO | 2018-05-04 | — | — | CN | disclosed |
| WO-2018080933-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-0711813-A2 | Coating varnish composition and antifouling coating composition | Hitachi Chemical Co., Ltd. (JP) | 1996-05-15 | — | — | EP | disclosed |
| EP-0659848-A2 | Coating composition and antifouling paint | Hitachi Chemical Co., Ltd. (JP) | 1995-06-28 | — | — | EP | disclosed |
| EP-0326222-B1 | Process for preparing substituted imidazoline fabric conditioning compounds | PROCTER & GAMBLE (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5154841-A | Cyclizing a polyamine with a fatty acid, ester, acyl halide or anhydride, followed by catalytic esterification with fatty acid ester or glycerides; titanium or tin alkoxides, salts, halides or alkyl halide as catalysts | THE PROCTER & GAMBLE COMPANY (US) | 1992-10-13 | — | — | US | disclosed |
| US-5030521-A | Magnetic recording medium using a fatty acid ester lubricant wherein the alcohol component is branched at the number one carbon position | FUJI PHOTO FILM CO., LTD. (JP) | 1991-07-09 | — | — | US | disclosed |
| US-5013846-A | Process for preparing substituted imidazoline fabric conditioning compounds | THE PROCTER & GAMBLE COMPANY (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0375029-A2 | Process for preparing substituted imidazoline fabric conditioning compounds | THE PROCTER & GAMBLE COMPANY (US) | 1990-06-27 | — | — | EP | disclosed |
| EP-0326222-A2 | Process for preparing substituted imidazoline fabric conditioning compounds | THE PROCTER & GAMBLE COMPANY (US) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | DHPS, SRD5A2, SRD5A1 | LMNA 974/4885MAPT 2239/4885MAPK1 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.